ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers [Seeking Alpha]
ChemoCentryx, Inc. (CCXI)
Last chemocentryx, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chemocentryx.com
Company Research
Source: Seeking Alpha
ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers Summary CCX140 is a CCR2 chemokine receptor antagonist in two Phase 2 clinical trials for sub-nephrotic primary FSGS (LUMINA-1) and nephrotic syndrome primary FSGS (LUMINA-2). Focal Segmental Glomerulosclerosis is a rare debilitating, chronic progressive glomerular disease that limits kidney function. There are no FDA approved therapies. Mechanistically, CCX140 is proposed to improve podocyte health and subsequent kidney function. Clinically, injury/loss of the visceral epithelial cells, podocytes, is associated with the initiation and progression of FSGS. Due to the complexity and heterogeneity of FSGS, it is likely that more than one therapeutic agents including CCX140 may be needed to provide clinically effective benefits to FSGS patients. Voclosporin by Aurinia is also being clinically evaluated in FSGS. I provide updates. Market Assessment ChemoCentryx ( CCXI chemokine biology NASH HIV CCX140 is a
Show less
Read more
Impact Snapshot
Event Time:
CCXI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCXI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCXI alerts
High impacting ChemoCentryx, Inc. news events
Weekly update
A roundup of the hottest topics